This study is being done to evaluate the long term safety of ARQ-151 cream 0.15% and ARQ-151 cream 0.5% in subjects with mild to moderate eczema (atopic dermatitis). Eligible subjects will enroll in the long term safety study after they have successfully completed the preceding study. Study medication will be applied topically for 52 weeks at home. All affected areas, except on the scalp, will be treated. For the first 4 weeks of study, all subjects will apply study medication once a day in the areas identified and treated during the preceded study. Beginning at the Week 4 visit, any subject who achieves vIGA-AD of ‘0-clear' as confirmed by the Investigator at a scheduled or unscheduled clinic visit, will switch to twice weekly (BIW) maintenance treatment. For maintenance therapy, study medication will be applied on two nonconsecutive days per week.
Dermira, Inc./ Eli Lilly and Company has begun a study of an investigational drug (also known as the "study drug") called lebrikizumab as a possible treatment for moderate-to-severe atopic dermatitis. Patients who successfully complete the first Lebrikizumab study will be eligible for this study. This study will last approximately 62 weeks, and you will need to come to the study center at least 8 times over this period. The study is divided into 2 time periods: a Treatment Period and a Follow up Period. During the treatment period, participants will be given Lebrikizumab ever 2 weeks or every 4 weeks but all participants will receive injections every 2 weeks. During each study period, you will have 1 or more visits with your study doctor at the study center. All visits will last about 1 to 2 hours.
This study is being done to evaluate the safety and efficacy of ARQ-151 cream in subjects with mild to moderate eczema (atopic dermatitis) after application once every day for a month. Results will be compared against a vehicle (placebo). The vehicle is a dummy drug made from the same base product used to make ARQ-151 cream, but it does not contain any active study drug. ARQ-151 is a cream that contains the active ingredient roflumilast. Roflumilast is marketed in Canada, the United States, and other countries as a tablet (pill taken by mouth) for flares of a specific chronic lung disease. You will apply the study drug on your eczema lesions once a day for 28 days. The study doctor will tell you which lesions to treat. Any newly appearing eczema lesions that arise during the study must also be treated.
This study is going to test a cold atmospheric plasma device (CAP), in particular a floating electrode-dielectric barrier device (FE-DBD), to treat warts and molluscum. The treatment device in this study generates cold atmospheric plasma (gaseous ionized molecules) to rid the virus from the body. Based on the successes of previous dermatologic studies, FE-DBD is being tested for this study to treat warts and molluscum. Patients will be enrolled to test the efficacy and safety of this device.
Patients aged between 4-21 years are eligible to participate. The duration of the study is 4-12 weeks depending on treatment clearance. The number of lesions will be chosen by the dermatologist. Patients will receive standard of care therapy and/or NTAP depending on the number of lesions. Safety profile and patient tolerability will be measured, as well as changes in size, pain and appearance. Photographs and clinical impression will be used to measure treatment response. Pain and tolerability will be assessed by a visual analogue scale and tolerability assessment scale.
Eli Lilly and company has begun a study of an investigational drug called Lebrikizumab as a possible treatment for moderate-to-severe atopic dermatitis (AD). This study will also include 2 vaccines commonly used in adults with moderate-to-severe AD: meningococcal vaccines (MCV) and tetanus, diphtheria, and pertussis (Tdap). The main purpose of this study is to learn whether Lebrikizumab could impact how effective certain vaccines may be and how effective and safe the study drug is in patients with moderate-to-severe AD compared with placebo. A placebo is an inactive material that looks like the study drug but does not contain any active study drug. The study duration is approximately 32 weeks, and participants will need to come to the study center at least 7 to 11 times over this period.
The purpose of this study is to help us understand how safe and effective a new drug called bimekizumab is for long-term use in treating hidradenitis suppurativa. Bimekizumab is a new drug that may eventually be used in the treatment of hidradenitis suppurativa. It is investigational, which means that is it still being tested, and has not yet been approved for treatment by the health authorities, such as the US Food and Drug Administration (FDA). Bimekizumab acts on the immune system to help reduce inflammation and other symptoms. In this study, bimekizumab is administered in three different dosing regimens. Among 490 study participants, 420 of them will be receiving bimekizumab (140 study participants under each dose of bimekizumab) and 70 of them will be receiving placebo for the first 16 weeks.
Galderma has begun a study of an investigational drug called nemolizumab as a possible treatment for atopic dermatitis. Participants who had been previously enrolled in nemolizumab AD Phase 3 pivotal study will be eligible to enroll for the long term extension. Patients who have completed their initial 16 week treatment period who do not qualify for the maintenance period will be given the option to enroll immediately into the long term extension study. Additionally, subjects who complete the maintenance periods (week 48 visit) may also be eligible to enroll in the long term extension study.
This is a 2-year, longitudinal, observational study of adult patients (ages 18 and above) being treated for moderate to severe plaque psoriasis.
Patients being prescribed or initiating medical therapy with a new biologic drug (such as risankizumab, guselkumab, brodalumab, tildrakizumab, ixekizumab, adalimumab, etanercept, ustekinumab, secukinumab, certilizumab pegol, infliximab, or apremilast) for the treatment of plaque psoriasis will be eligible for enrollment. The study will be conducted to gather data from enrolled patients' electronic health records, prospective physician-reported information provided by the patients' dermatologists, and information collected from questionnaires and surveys completed by the enrolled patients.
Patients will be screened and enrolled at a regularly scheduled clinic visit. Retrospective medical records from patients who provide consent/assent and meet all inclusion and exclusion criteria will be obtained by the research site. Records will include but will not be limited to: hospitalizations, emergency room visits, procedures, and medical costs. Physician reported outcomes will be recorded at regularly scheduled visits. Patients will also be asked to complete patient reported outcome (PRO) surveys and questionnaires to record data regarding demographics, clinical characteristics of psoriatic disease, comorbidities, family history, occupation and lifestyle factors, use of PsO support programs, contact information, concomitant medication use, medication side effects, and symptom characteristics.
During the follow-up period, the research site will prospectively submit the research subjects' medical records approximately every 3 to 12 months, for up to 2 years. Patients will be asked to complete PRO surveys electronically at regular intervals during this follow-up period.
This registry is observational study about patients who are 12 years or older who have Atopic Dermatitis (AD) that are initiating treatment with DUPIXENT.
Patients will be screened and enrolled at a regularly scheduled clinic visit. During the screening and enrollment period, patients will provide medical history, demographic information, complete patient reported outcome (PRO) surveys and physician assessments. During the follow-up period, patients will complete PRO surveys and physician assessments at regular intervals during this follow-up period. Participation in this study will involve at least 12 visits that will take place over a period of 5 years.
Galderma has begun a study of an investigational drug called nemolizumab as a possible treatment for atopic dermatitis. Participants will be randomized to receive either Nemolizumab or placebo once every 4 weeks. Both Nemolizumab and Placebo will be given through a subcutaneous injection. At Visit 6 (Week 16), if the study doctor determines the participant is responding to the study treatment the participants will once again be randomized to either receive Nemolizumab and placebo or just placebo. At visit 6, if the participant is not responding to the medication the patient will have a follow up visit and their participation in the study will end.